Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Fremanezumab, ATC N02CD03

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 523 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fremanezumab, ATC N02CD03

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

10 / 100

Facteurs de risque

No indication of the expected number of patients or sales volume, making revenue estimation impossible.

Open-house agreements automatically become void if a regular rebate contract for the same substance is signed, potentia...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive pharmaceutical discount agreements for Fremanezumab (ATC N02CD03)
  • Single lot covering the active substance only
Afficher le résumé complet

This is an open-house model (not a formal procurement procedure) by AOK Bayern for non-exclusive pharmaceutical discount agreements for Fremanezumab (ATC N02CD03). Any qualified pharmaceutical company can join at any time during the contract period (01.04.2026 – 31.03.2028). There is no selection, no competition, and no estimated value disclosed. The tender is governed by German social law (§130c SGB V) and explicitly excluded from procurement law. Only one lot is defined.

Risques

No indication of the expected number of patients or sales volume, making revenue estimation impossible.

Open-house agreements automatically become void if a regular rebate contract for the same substance is signed, potentia...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as contractual partners

Administrative

  • Submission of a signed and completed 'Eigenerklärung zur Zuverlässigkeit' (declaration of reliability)
  • Submission of the signed contract including the annex 'Festlegung der vertragsgegenständlichen Arzneimittel'

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Fremanezumab, ATC N02CD03

Non-exclusive discount agreements for the active substance Fremanezumab (ATC N02CD03). Contractual terms are identical and non-negotiable. Contracts have a fixed end date of 31.03.2028. Earliest start is 01.04.2026. Submission of signed contract and reliability declaration required. Submission via paper or electronically with qualified electronic signature.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 03, 2028

Détails de la procédure

Date de publication
15 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
109906-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30